Visceral fat vs. subcutaneous fat
Visceral fat sits deep in the abdomen, around the internal organs. It behaves differently from subcutaneous fat, the softer fat directly beneath the skin that can be pinched. Visceral fat is metabolically active and is linked to metabolic health. Tesamorelin is a medication most closely associated with visceral fat.
What is tesamorelin?
Tesamorelin is a prescription growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to increase the body's own production of growth hormone and insulin-like growth factor 1 (IGF-1). Tesamorelin is not synthetic human growth hormone.
It is modeled on the body's natural GHRH and has been modified to remain active longer than naturally occurring GHRH, creating a stronger and more sustained signal to the pituitary gland. It works upstream in the growth hormone pathway: it prompts the body to release its own growth hormone rather than supplying growth hormone directly.
A prescription form of tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Use for other body-composition or wellness goals is considered off-label.
How tesamorelin works
The pituitary gland releases growth hormone in pulses, with some of the strongest natural secretion occurring during sleep. The hypothalamus helps regulate this process by producing GHRH.
Tesamorelin binds to GHRH receptors on the pituitary gland and signals it to release growth hormone. Growth hormone then stimulates the liver and other tissues to produce IGF-1.
Growth hormone and IGF-1 are involved in several processes, including:
- fat metabolism
- protein turnover
- lean tissue maintenance
- cellular repair
- bone and connective-tissue activity
- energy use
In clinical trials in adults with HIV-associated abdominal fat accumulation, tesamorelin reduced visceral adipose tissue while having less effect on subcutaneous fat. Because it works through the pituitary gland, the body's natural feedback mechanisms remain involved in regulating growth hormone production.
Tesamorelin is considered weight-neutral in its FDA-approved use. Its studied effect is on visceral fat distribution rather than overall body weight.
Timeline and duration in research
Clinical studies of tesamorelin and visceral fat commonly measured outcomes after about six months of treatment. Research has also found that visceral fat can return after tesamorelin is stopped.
Who should not use tesamorelin
Tesamorelin affects growth hormone and IGF-1 levels and is a prescription medication that requires medical evaluation. Situations in which it may not be appropriate include:
- pregnancy, planning pregnancy or breastfeeding
- active cancer
- a disrupted hypothalamic-pituitary axis
- known hypersensitivity to tesamorelin or its formulation
- uncontrolled diabetes or significant glucose instability
- persistently elevated IGF-1
- critical illness or recovery from major surgery
Risks and side effects
Commonly reported side effects of prescription tesamorelin include injection-site redness or itching, joint discomfort, muscle aches, pain in the extremities and fluid retention. Fluid retention can contribute to swelling, joint pain or carpal tunnel symptoms.
Tesamorelin raises IGF-1 and may affect glucose control, which is why IGF-1, fasting glucose and hemoglobin A1C are commonly monitored during treatment.
Tesamorelin is given by subcutaneous injection, generally into the fatty tissue of the abdomen. Temporary redness, itching, tenderness or bruising at the injection site may occur.
How tesamorelin compares with related options
Tesamorelin vs. sermorelin
Both stimulate natural growth hormone release through the GHRH receptor, and neither is human growth hormone. Sermorelin is a shorter GHRH analog and is generally considered milder. Tesamorelin is more potent and longer-acting, generally produces a greater increase in growth hormone and IGF-1, and has stronger clinical evidence for reducing visceral abdominal fat.
Tesamorelin vs. ipamorelin
Tesamorelin acts through the GHRH receptor. Ipamorelin is a growth hormone secretagogue that acts through the ghrelin receptor. Some clinicians combine them because the pathways are different. Strong evidence that combination therapy improves long-term outcomes is limited.
Tesamorelin vs. human growth hormone
Tesamorelin prompts the pituitary gland to release growth hormone. Human growth hormone supplies the hormone directly and bypasses the body's release mechanism. The two are medically distinct, have different approved uses and are not interchangeable.
Tesamorelin vs. GLP-1 medications
GLP-1 medications such as semaglutide and tirzepatide act mainly through appetite, satiety, gastric emptying and glucose regulation, and can reduce both visceral and subcutaneous fat as total body weight decreases. Tesamorelin works through growth hormone signaling, is more specifically associated with visceral fat and is weight-neutral in its approved use.
Frequently asked questions
Is tesamorelin a weight-loss medication?
Tesamorelin is not approved for general weight loss and is considered weight-neutral in its approved indication. Its studied effect is on visceral abdominal fat.
Does tesamorelin contain growth hormone?
No. Tesamorelin is a GHRH analog. It signals the pituitary gland to increase the body's own growth hormone production, which in turn raises IGF-1.
How is tesamorelin different from sermorelin?
Both act through the GHRH pathway. Tesamorelin is generally more potent and longer-acting and has stronger clinical evidence for reducing visceral abdominal fat.
What lab tests are associated with tesamorelin?
Monitoring commonly includes IGF-1, fasting glucose and hemoglobin A1C.
This article is for general educational purposes only and is not medical advice.
